Li-Juan Gui

Dr. Li-Juan Gui


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YMYi Mou
Yi Mou
SWShuai Wen
Shuai Wen
HSHong-Kai Sha
Hong-Kai Sha
YZYAO ZHAO
YAO ZHAO
LGLi-Juan Gui
Li-Juan Gui
Zhengyu JiangZhengyu Jiang
Zhengyu Jiang
Caffeic acid (CA) is a polyphenolic acid compound widely distributed in plant seeds. As natural compounds with high research interest, caffeic acid and its derivatives show good activity in the treatment of tumors and inflammation and have antibacterial properties. In recent years, caffeic acid derivatives have been studied extensively, and these derivatives fall roughly into three categories: (1) caffeic acid ester derivatives, (2) caffeic acid amide derivatives, (3) caffeic acid hybrids. These caffeic acid analogues exert mainly antibacterial and antioxidant activities. Among the caffeic acid analogues summarized in this paper, compounds 1g and CAP10 have good activity against Candida albicans, and their MIC50 is 32 µg/mL and 13 μM, respectively. In a DPPH assay, compounds 3k, 5a, CS2, Phellinsin A and 8j showed strong antioxidant activity, and their IC50 values are 18.6 μM, 67.85 μM, 40.29 μM, 0.29 ± 0.004 mM, 4774.37 ± 137.20 μM, respectively. Overall, compound CAP10 had the best antibacterial activity and compound 3k had the best antioxidant activity. This paper mainly summarizes and discusses some representative caffeic acid analogs, hoping to provide better drug design strategies for the subsequent development of caffeic acid analogs.

13 December 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
JLJingjing Lin
Jingjing Lin
SWShiya Wang
Shiya Wang
MCMingyi Cao
Mingyi Cao
YPYuhan Pan
Yuhan Pan
ZDZhiyue Dai
Zhiyue Dai
LGLi-Juan Gui
Li-Juan Gui

8 March 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
YMYi Mou
Yi Mou
SWShuai Wen
Shuai Wen
YWYan Wang
Yan Wang
YZYAO ZHAO
YAO ZHAO
LLLi Ying-Ping Li
Li Ying-Ping Li
MXMing Xiang Xu
Ming Xiang Xu
The treatment of ulcerative colitis (UC) has been a major medical challenge due to the lack of safe and effective drugs. Molecular hybridization is a promising strategy for the development of drugs with pleiotropic activity, which has been demonstrated in a wide range of diseases. Tofacitinib has exhibited significant effects on the remission of UC, but a series of adverse effects have occurred during its clinical application. Herein, we propose to utilize a molecular hybridization strategy to link tofacitinib with a cytoprotective H2S donor (ADTOH) to obtain a series of hybridized molecules ZX-4C~ZX-6C. Among them, ZX-4C exhibited the best performance in the H2S release rate and the cytoprotective effects against dextran sulfate sodium (DSS)-induced injury. The in vivo studies showed that ZX-4C could effectively alleviate DSS-induced colitis by enhancing oxidative stress defense and reducing the inflammatory response, demonstrating that it is more potent than the parent drugs. The data from the present study support that this molecular hybridization strategy provides a promising avenue for the treatment of UC.